OakChart

Biomarin Pharmaceutical Inc

BMRNHealthcare·Biotechnology·USA·Large·NASD·Nov 11 • 3:59 PM ET

58.33+1.20 (2.10%)
2026-11-12 02:08 CET
Market cap
11,065.80 USD m
Revenue, TTM
3,694.57 USD m
Net income, TTM
-19.11 USD m
Free cash flow, TTM
557.86 USD m
EPS diluted, TTM
-0.10
P/E
-
Compare

Price

BMRN against its 20, 50 and 200-day averages
2050200miss
50.0055.0060.0065.0070.002.7M5.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BMRNclose 58.3320-day 56.3950-day 59.25200-day 58.4658.3352w high52w low

17.8% under the 52-week high of 70.98 on 12 Aug 2026. 52-week low 49.26 on 18 May 2026. Last 15 sessions, 14.4% high to low

Volume 0.74× normal · the line is the 50-bar volume average

Profile

BMRN
52-week range, 42% of the way up
49.2670.98

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

IndexRUI
Employees3221
IPOJul 23, 1999
Beta0.23
ATR, 14d1.84
Rel volume0.74
Short float7.39%
Insider own1.29%
Inst own103.46%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap11.30B
Enterprise Value14.77B
Income-19.11M
Sales3.69B
Book/sh32.30
Cash/sh3.80
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees3221
IPOJul 23, 1999

Ratios

P/E-
Forward P/E9.07
PEG0.15
P/S3.06
P/B1.81
P/C15.35
P/FCF20.25
EV/EBITDA15.16
EV/Sales4.00
Quick Ratio1.32
Current Ratio2.44
Debt/Eq0.67
LT Debt/Eq0.56
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.10
EPS next Y6.43
EPS next Q0.82
EPS this Y68.19%
EPS next Y112.48%
EPS next 5Y62.21%
EPS past 3/5Y34.05% -16.79%
Sales past 3/5Y16.55% 11.97%
EPS Y/Y TTM-103.57%
Sales Y/Y TTM19.76%
EPS Q/Q-296.31%
Sales Q/Q30.22%
EarningsNov 02 AMC
EPS/Sales Surpr.566.53% 0.21%

Ownership

Insider Own1.29%
Insider Trans-0.83%
Inst Own103.46%
Inst Trans-0.17%
ROA-0.20%
ROE-0.31%
ROIC-0.20%
Gross Margin71.28%
Oper. Margin19.19%
Profit Margin-0.52%
SMA203.44%
SMA50-1.55%
SMA200-0.23%
Trades-

Technical

Shs Outstand193.68M
Shs Float191.20M
Short Float7.39%
Short Ratio6.28
Short Interest14.12M
52W High70.98 -17.82%
52W Low49.26 18.41%
Volatility2.99% 3.15%
ATR (14)1.84
RSI (14)54.64
Beta0.23
Rel Volume0.74
Avg Volume2.25M
Volume1,657,185

Performance

Perf Week2.10%
Perf Month7.26%
Perf Quarter-14.88%
Perf Half Y8.93%
Perf YTD-1.85%
Perf Year6.19%
Perf 3Y-30.54%
Perf 5Y-28.38%
Perf 10Y-36.22%
Recom1.55
Target Price90.81
Prev Close57.13
Price58.33
Change %2.10%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 15, 2026ResumedUUBSBuy$88+50.9%
Oct 12, 2026UpgradeRRaymond JamesOutperform → Strong Buy$109+86.9%
Aug 19, 2026InitiatedBBMO Capital MarketsOutperform$98+68.0%
May 19, 2026InitiatedCCitigroupBuy$75+28.6%
May 11, 2026ResumedGGoldmanNeutral$69+18.3%
Apr 27, 2026ResumedMMorgan StanleyOverweight$120+105.7%
Jan 28, 2026ResumedBBarclaysOverweight$80+37.2%
Jan 20, 2026UpgradeCCanaccord GenuityHold → Buy$98+68.0%
Dec 03, 2025DowngradeLLeerink PartnersOutperform → Market Perform$60+2.9%
Nov 06, 2025DowngradeSStifelBuy → Hold$61+4.6%

Peers

Mkt cap
TickerCompanyMkt cap
ASNDAscendis Pharma A/S17.03B
BBIOBridgeBio Pharma Inc15.49B
PTCTPTC Therapeutics Inc5.42B
RAREUltragenyx Pharmaceutical Inc1.70B
SRPTSarepta Therapeutics Inc1.79B
ALNYAlnylam Pharmaceuticals Inc21.41B
IONSIonis Pharmaceuticals Inc4.72B
KRYSKrystal Biotech Inc9.15B
VRTXVertex Pharmaceuticals Inc138.69B
SNYSanofi ADR115.43B

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Davis George EricEVP, Chief Legal OfficerSep 02 '26Sale66.2817,5571,163,74861,003Sep 03 06:41 PM
Davis George EricOfficerSep 02 '26Proposed Sale66.2817,5571,163,756Sep 02 02:55 PM
Friberg Gregory REVP, Chief R&D OfficerMay 07 '26Sale53.853,281176,68251,818May 11 05:01 PM
Friberg Gregory ROfficerMay 07 '26Proposed Sale53.853,281176,682May 07 01:17 PM
Guyer Charles GregEVP, Chief Technical OfficerMar 11 '26Sale60.4616,486996,74479,953Mar 12 07:55 PM
Guyer Charles GregOfficerMar 11 '26Proposed Sale60.4616,486996,749Mar 11 03:23 PM
Friberg Gregory REVP, Chief R&D OfficerFeb 26 '26Sale60.386,326381,93737,578Feb 26 08:39 PM
Davis George EricEVP, Chief Legal OfficerFeb 26 '26Sale61.3626,0611,599,10372,453Feb 26 08:31 PM
Friberg Gregory ROfficerFeb 26 '26Proposed Sale60.386,326381,937Feb 26 01:59 PM
Davis George EricOfficerFeb 26 '26Proposed Sale61.3626,0611,599,103Feb 26 10:18 AM

Held by

AUM
TickerCompanyAUM
IJHiShares Core S&P Mid-Cap ETFAUM: 124.48B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.03B
DFSVUS Small Cap Value Portfolio ETF Class SharesAUM: 8.52B
IBBiShares Biotechnology ETFAUM: 11.36B
MDYState Street SPDR S&P MIDCAP 400 ETF TrustAUM: 26.22B

News

latest 14 of 200
  • BioMarin to Participate in Upcoming Investor Conferences (PR Newswire)
  • BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs (InvestorsHub)
  • BioMarin Tops Depressed EPS Bar And Crosses $1 Billion, But A Guidance Cut And Softer VOXZOGO Trends Complicate The Story (Earnings Whispers)
  • BioMarin: Q3 Earnings Snapshot (Associated Press)
  • BioMarin Reports Third Quarter 2026 Financial and Operating Results (PR Newswire)
  • Stocktwits Biotech Dealmaker: BioMarins Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking (Stocktwits)
  • BioMarin Must Prove Voxzogo Can Hold Ground As Amicus Lifts Revenue Toward $1 Billion (Earnings Whispers)
  • BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET (PR Newswire)
  • Is Vertex Stock Worth More Than Its Competitors? (Trefis)
  • BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting (PR Newswire)
  • BioMarin Appoints Cara Bauer as Chief People Officer (PR Newswire)
  • BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress (PR Newswire)
  • BioMarin and Profluent partner on AI-designed enzyme therapies (Pharmaceutical Technology)
  • BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-020.230-0.049-0.6301,0251,02315
2026Q22026-08-061.2000.9470.230989.71932.0315
2026Q12026-05-040.7600.6920.543766752.5319
2025Q42026-02-23-0.2400.169-0.242874.57833.7312
2025Q32025-10-27-0.160-0.280-0.160776.13777.4812
2025Q22025-08-041.2300.8611.230825761.9523
2025Q12025-05-010.9500.6820.954745.15738.6616
2024Q42025-02-190.6400.5340.645747712.322
2024Q32024-10-290.5500.5310.547745.74703.4320
2024Q22024-08-050.5500.3580.548712.03663.9811
2024Q12024-04-240.4600.3120.459648.8651.8318
2023Q42024-02-220.1100.1970.106646.21638.8215
2023Q32023-11-010.2100.2200.211581.33603.8421
2023Q22023-07-310.2900.2110.292595.28595.2319
2023Q12023-04-260.2700.1690.262596.42570.3519
2022Q42023-02-270.000-0.058-0.001537.54537.6218

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.130-0.288-0.1331,7041,707
2020FY4.4104.0334.5251,8601,858
2021FY-0.350-0.348-0.3501,8461,842
2022FY0.7500.6920.7492,0962,097
2023FY0.8700.9790.8752,4192,413
2024FY2.2102.2582.2072,8542,818
2025FY1.8002.2091.8003,2213,179
2026FY-3.028--3,868
2027FY-6.433--4,456
2028FY-7.683--4,835
2029FY-8.675--5,219
2030FY-9.248--5,477

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-03210191,0881,0581,121
2026Q4S2026-11-0224631,1351,0861,252
2026Q4S2026-11-0124621,1371,0861,252
2026Q4S2026-10-2924721,1371,0861,252
2026Q4S2026-10-2824721,1371,0861,252
2026Q4S2026-10-2624721,1371,0861,252
2026Q4S2026-10-2124621,1361,0861,252
2026Q4S2026-10-20241151,1361,0861,252
2026Q4S2026-10-19241151,1351,0861,252
2026Q4S2026-10-16241061,1351,0861,252
2026Q4S2026-10-1524881,1321,0861,252
2026Q4S2026-10-1424881,1321,0861,252
2026Q4S2026-10-1324881,1321,0861,252
2026Q4S2026-10-1223881,1271,0861,153

Estimate history

EPS, annual-0.67-0.436-0.1334.525-0.350.7490.8752.2071.805-0.1035
Period201720182019202020212022202320242025TTM
EPS, quarterly0.5470.6450.9541.23-0.16-0.2420.5430.23-0.635
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1319.0231497.2171686.3761842.3331846.0792047.4982419.4122839.2073241.8643694.57
Period201720182019202020212022202320242025TTM
Sales, quarterly742.375738.222732.6827.473786.772895.019778.62996.3831024.546
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual175.844178.253179.838181.741183.913186.251188.598190.761192.3193.677
Period201720182019202020212022202320242025MRQ
Shares, quarterly190.554190.761191.756192.002192.099192.3193.269193.536193.677
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3,694.573,241.862,839.212,419.412,047.501,846.081,842.331,686.381,497.22
Cost of Goods Sold Incl. D&A1,061.20736.83623.49577.07546.46532.45586.47412.97345.56
Gross Profit2,633.372,505.042,215.721,842.351,501.041,313.631,255.861,273.411,151.65
Selling, General and Administrative Excl. Other1,924.381,612.731,685.911,647.911,492.571,384.971,360.731,387.221,310.30
Research and Development758.69700.97747.18746.77649.61628.79628.12715.01696.33
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income708.99892.30529.80194.448.47-71.34-104.87-113.81-158.65
Interest Expense136.6610.9012.6717.3415.9715.3429.3123.4643.66
Unusual Expense556.06462.2261.8620.713.539.554.5725.8712.83
Net Income Before Taxes43.66482.48541.76188.56149.58-75.35-42.32-94.81-142.71
Income Taxes62.78133.58114.9020.928.02-11.27-901.42-70.96-65.49
Consolidated Net Income-19.11348.90426.86167.65141.56-64.08859.10-23.85-77.21
Net Income From Continuing Operations-19.11348.90426.86167.65141.56-64.08859.10-23.85-77.21
Net Income-19.11348.90426.86167.65141.56-64.08859.10-23.85-77.21
EPS (Recurring)1.923.442.430.950.76-0.314.54-0.03-0.39
EPS (Basic, Before Extraordinaries)-0.101.822.250.890.76-0.354.75-0.13-0.44
EPS (Diluted)-0.101.802.210.880.75-0.354.53-0.13-0.44
EBITDA973.94971.86626.23298.83110.4436.701.01-8.51-63.15
Non-Operating Income (Expense)27.3963.2986.4932.16160.6120.8796.4368.3372.44
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense173.55143.31159.24163.61155.08144.00138.49116.70117.57
Price To Earnings Ratio--39.58126.25248.71-20.16--
Price To Sales Ratio3.143.624.557.649.558.759.128.9810.07
Gross Margin71.2877.2778.0476.1573.3171.1668.1775.5176.92
Operating Margin19.1927.5218.668.040.41-3.86-5.69-6.75-10.60
Net Margin-0.5210.7615.036.936.91-3.4746.63-1.41-5.16
Shares Outstanding193.68192.30190.76188.60186.25183.91181.74179.84178.25
Market Capitalization11,065.8011,065.8012,527.0218,162.4419,233.5116,220.4415,918.3715,187.2915,161.98

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1,024.55996.38778.62895.02786.77827.47732.60738.22
Cost of Goods Sold Incl. D&A304.87276.29199.48280.56144.93154.94151.56145.79
Gross Profit719.67720.10579.14614.46641.84672.54581.04592.43
Selling, General and Administrative Excl. Other465.31515.68428.77514.62456.93371.03350.13454.31
Research and Development180.53206.95178.80192.41188.51161.31158.73173.51
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income254.37204.42150.3699.84184.91301.51230.91138.12
Interest Expense55.6363.3014.962.782.582.682.862.58
Unusual Expense336.9386.828.31124.00220.9624.0716.96-14.52
Net Income Before Taxes-131.7761.38141.20-27.15-26.32297.87238.09169.64
Income Taxes-8.9416.6235.6819.424.4257.3452.4044.70
Consolidated Net Income-122.8344.76105.53-46.57-30.74240.53185.69124.94
Net Income From Continuing Operations-122.8344.76105.53-46.57-30.74240.53185.69124.94
Net Income-122.8344.76105.53-46.57-30.74240.53185.69124.94
EPS (Recurring)0.580.540.570.210.651.321.010.59
EPS (Basic, Before Extraordinaries)-0.630.230.55-0.24-0.161.250.970.66
EPS (Diluted)-0.630.230.54-0.24-0.161.230.950.64
EBITDA384.83302.06166.78120.28203.40320.07252.98161.73
Non-Operating Income (Expense)6.427.0814.11-0.2212.3123.1127.0019.58
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense42.2959.8034.3337.1338.9237.5529.7840.29
Price To Earnings Ratio-41.7531.7022.2716.0420.4032.1439.58
Price To Sales Ratio3.143.223.403.523.373.564.754.55
Gross Margin70.2472.2774.3868.6581.5881.2879.3180.25
Operating Margin24.8320.5219.3111.1623.5036.4431.5218.71
Net Margin-11.994.4913.55-5.20-3.9129.0725.3516.92
Shares Outstanding193.68193.54193.27192.30192.10192.00191.76190.76
Market Capitalization11,298.2311,059.7110,864.3311,417.3310,399.5310,541.9313,486.0312,527.02

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,560.611,137.711,073.811,291.541,013.881,065.39753.811,084.311,395.97
Short Term Receivables908.21660.53633.70461.32373.40448.35377.40342.63261.37
Inventories1,298.881,232.651,107.18894.08776.67698.55680.27530.87475.77
Other Current Assets162.98201.53141.39104.52110.44129.93130.6698.4074.04
Total Current Assets3,930.693,232.432,956.092,751.462,274.392,342.221,942.142,056.222,207.14
Net Property, Plant & Equipment991.801,076.791,112.211,114.321,081.881,089.581,070.30948.68896.70
Total Investments and Advances498.21536.27615.38338.32515.72293.11433.69246.19390.76
Intangible Assets507.04523.58521.50534.77584.85613.47653.62688.85714.55
Deferred Tax Assets1,508.701,489.371,545.811,505.411,449.081,432.15549.42523.02443.42
Other Assets157.59130.5190.62130.7997.4177.4940.8726.2424.88
Total Assets7,594.026,988.946,841.606,375.076,003.325,848.024,690.044,489.204,677.45
Short Term Debt Incl. Current Port. of LT Debt8.6923.07502.6610.3810.4611.75372.580.00360.95
Accounts Payable312.77235.40315.51231.24193.00191.43240.98207.62166.62
Income Tax Payable3.6712.572.6516.211.219.66--5.53
Other Current Liabilities433.91335.95356.21331.06335.14279.70318.94315.62283.43
Total Current Liabilities759.03606.991,177.02588.88539.82492.55932.50523.24816.52
Long Term Debt634.19626.39631.221,109.531,112.921,119.63537.04830.42813.52
Provision for Risks Charges0.000.000.000.000.000.000.000.00135.32
Deferred Tax Liabilities-------62.0744.32
Other Liabilities113.8097.5781.8173.5079.84129.8498.12105.5359.10
Total Liabilities1,507.021,330.951,890.051,771.921,732.591,742.021,567.661,521.261,868.79
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity6,087.005,657.994,951.554,603.164,270.744,106.003,122.382,967.942,808.66
Total Shareholders Equity6,087.005,657.994,951.554,603.164,270.744,106.003,122.382,967.942,808.66
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity6,087.005,657.994,951.554,603.164,270.744,106.003,122.382,967.942,808.66
Total Liabilities & Stockholders Equity7,594.026,988.946,841.606,375.076,003.325,848.024,690.044,489.204,677.45
Book Value Per Share31.6529.6626.2524.7123.2222.5917.3616.6515.97
Tangible Book Value Per Share29.0226.9223.4921.8420.0419.2213.7312.7911.91
Full-Time Employees3,2213,0403,4013,0823,0453,0593,0012,8492,581
Price to Book Ratio1.772.313.714.213.803.884.875.115.56
Return on Assets4.796.172.542.29-1.0816.30-0.52-1.68-2.69
Return on Equity5.948.053.513.19-1.5323.77-0.78-2.67-4.20
Return on Invested Capital5.196.793.002.48-1.1916.44-0.65-2.03-3.23
Quick Ratio3.473.291.573.152.773.341.352.922.12
Current Ratio5.185.332.514.674.214.762.083.932.70

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-19.11348.90426.86167.65141.56-64.08859.10-23.85-77.21
Depreciation264.9579.5696.43104.39101.97108.04105.17105.3095.67
Other Funds (Non Cash)774.44644.46209.86268.7580.84210.15234.42150.66119.55
Funds from Operations993.401,121.65789.24495.80272.29238.50309.78149.3569.63
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-316.78-293.66-216.40-336.54-96.3866.03-224.42-101.09-49.42
Cash from Operating Activities676.62827.99572.84159.26175.90304.5485.3648.2620.21
Capital Expenditures-121.12-110.97-97.42-107.61-131.54-119.22-137.52-163.41-144.62
Net Assets From Acquisitions-5,067.63-285.190.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments742.13-18.07222.77-3.638.19-246.0926.17108.19358.98
Purchase of Investments-68.41-355.88-410.25-868.50-611.81-937.14-529.66-632.02-634.75
Sale Or Maturity of Investments810.53337.80633.02864.86620.00691.05555.83740.21993.73
Other Uses-279.070.000.000.000.00-0.99-9.43-0.81-0.01
Other Sources0.000.0011.140.00103.330.0067.1625.0050.00
Cash from Investing Activities-4,725.70-414.24136.49-111.24-20.03-366.31-53.62-31.03264.35
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock13.4014.4649.2869.3569.3349.1921.9131.6167.49
Repurchase of Common Pref Stock0.000.000.000.000.000.00-50.000.000.00
Sale of Common Pref Stock13.4014.4649.2869.3569.3349.1971.9131.6167.49
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net3,569.390.00-494.99-2.29-2.60-3.04203.84-5.09-374.95
Change in Long Term Debt3,569.390.00-494.99-2.29-2.60-3.04203.84-5.09-374.95
Issuance of Long Term Debt3,584.390.000.000.000.000.00585.750.000.00
Reduction of Long Term Debt-15.000.00-494.99-2.29-2.60-3.04-381.91-5.09-374.95
Net Financing Active Other Cash Flow-46.92-56.85-80.74-85.79-85.38-46.20-44.64-101.20-80.54
Other Financing Activities Uses-46.92-56.85-80.74-85.79-85.38-46.20-44.64-101.20-80.54
Cash from Financing Activities3,535.88-42.39-526.45-18.73-18.65-0.05181.12-74.67-388.01
Exchange Rate Effect-0.90-2.524.831.310.03-0.06-1.150.90-0.60
Net Change in Cash-514.10368.84187.7230.60137.25-61.88211.71-56.54-104.05
Free Cash Flow557.86724.96487.4262.5754.94208.96-28.95-96.76-124.41
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow20.8216.1826.53295.26355.9377.31---
Deferred Taxes & Investment Tax Credit-48.7456.10-44.98-52.09-15.61-888.91-82.76-68.38

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments736.01874.002,222.431,560.611,477.841,432.12
Short Term Receivables1,076.361,061.05903.91908.21790.27855.86
Inventories1,796.071,782.521,273.221,298.881,382.171,340.17
Other Current Assets312.20254.05205.50162.98204.26177.18
Total Current Assets3,920.643,971.624,605.073,930.693,854.543,805.33
Net Property, Plant & Equipment980.08989.99958.07991.801,038.191,030.38
Total Investments and Advances11.429.46857.66498.21533.47530.95
Intangible Assets5,443.615,535.11400.86507.04429.31435.82
Deferred Tax Assets897.79888.581,500.601,508.701,509.111,427.02
Other Assets315.69328.68268.75157.59250.25226.83
Total Assets11,569.2311,723.448,591.027,594.027,614.877,456.34
Short Term Debt Incl. Current Port. of LT Debt691.00689.7615.978.6914.5215.72
Accounts Payable130.72406.98395.47312.77389.67310.80
Income Tax Payable18.929.143.013.6722.6113.40
Other Current Liabilities764.18558.12378.70433.91371.64344.33
Total Current Liabilities1,604.821,664.00793.15759.03798.44684.25
Long Term Debt3,514.973,527.941,430.28634.19596.66596.16
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities193.40209.81155.47113.80163.06148.82
Total Liabilities5,313.205,401.752,378.911,507.021,558.161,429.23
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6,256.036,321.696,212.116,087.006,056.716,027.11
Total Shareholders Equity6,256.036,321.696,212.116,087.006,056.716,027.11
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity6,256.036,321.696,212.116,087.006,056.716,027.11
Total Liabilities & Stockholders Equity11,569.2311,723.448,591.027,594.027,614.877,456.34
Book Value Per Share32.3032.6632.1431.6531.5331.39
Tangible Book Value Per Share4.194.0630.0729.0229.2929.12
Full-Time Employees---3,221--
Price to Book Ratio1.811.781.781.881.731.82
Return on Assets-0.200.763.424.797.209.05
Return on Equity-0.311.184.485.949.0711.62
Return on Invested Capital-1.260.451.38-0.69-0.463.63
Quick Ratio1.321.324.203.473.103.60
Current Ratio2.442.395.815.184.835.56

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-122.8344.76105.53-46.57-30.74240.53
Depreciation130.4797.6416.4120.4418.4918.56
Other Funds (Non Cash)347.7487.0650.42289.22275.6650.91
Funds from Operations325.62222.50181.58263.70249.76343.34
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-137.41-54.3939.07-164.05118.93-158.07
Cash from Operating Activities188.21168.11220.6599.64368.69185.27
Capital Expenditures-22.86-34.25-20.92-43.09-33.75-17.37
Net Assets From Acquisitions0.00-5,067.630.000.00-285.190.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.00741.490.64-12.024.77
Purchase of Investments0.000.00-25.79-42.61-110.83-113.16
Sale Or Maturity of Investments0.000.00767.2843.2598.81117.93
Other Uses-279.070.000.000.000.000.00
Other Sources-4.970.004.970.000.000.00
Cash from Investing Activities-306.90-5,101.88725.53-42.45-330.96-12.59
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.006.660.006.750.017.71
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.006.660.006.750.017.71
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-15.002,743.05841.350.000.000.00
Change in Long Term Debt-15.002,743.05841.350.000.000.00
Issuance of Long Term Debt-0.002,743.05841.350.000.000.00
Reduction of Long Term Debt-15.000.000.000.000.000.00
Net Financing Active Other Cash Flow-3.83-11.32-28.18-3.59-2.18-12.31
Other Financing Activities Uses-3.83-11.32-28.18-3.59-2.18-12.31
Cash from Financing Activities-18.832,738.38813.173.16-2.17-4.60
Exchange Rate Effect-0.49-3.041.411.220.74-3.06
Net Change in Cash-138.00-2,198.431,760.7661.5736.29165.01
Free Cash Flow159.92139.29199.7358.92340.24168.17
Price to Free Cash Flow20.8215.0714.5615.7612.5015.59

Revenue breakdown

ALDURAZYME2024: 183.89M 2025: 208.51M
BRINEURA2024: 169.08M 2025: 186.40M
KUVAN2024: 120.90M 2025: 99.53M
NAGLAZYME2024: 479.58M 2025: 485.40M
PALYNZIQ2024: 355.05M 2025: 433.31M
ROCTAVIAN2024: 26.07M 2025: 35.64M
Royalty And Other2024: 44.47M 2025: 53.49M
VIMIZIM2024: 739.78M 2025: 792.05M
VOXZOGO2024: 735.09M 2025: 926.92M
United States2024: 2.85B 2025: 3.22B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.39%14.1M191.2M2.25M
2026-10-156.31%12.1M191.1M2.11M
2026-09-306.03%11.5M191.1M1.94M
2026-09-155.27%10.1M191.1M1.97M
2026-08-315.17%9.9M191.1M2.01M
2026-08-145.34%10.2M191.1M2.19M
2026-07-316.57%12.5M190.5M2.08M
2026-07-157.53%14.3M190.2M2.05M
2026-06-307.31%13.9M190.2M2.09M
2026-06-156.58%12.5M190.1M2.05M
2026-05-296.10%11.6M190.2M2.01M
2026-05-155.97%11.4M190.3M1.97M
2026-04-305.67%10.8M190.4M1.98M
2026-04-155.36%10.2M189.5M2.08M
2026-03-314.66%8.8M189.6M2.17M
2026-03-134.48%8.5M189.6M2.46M
2026-02-274.36%8.3M189.6M2.48M
2026-02-134.55%8.6M189.3M2.69M
2026-01-304.16%7.9M190.0M2.73M
2026-01-153.89%7.4M190.0M2.91M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call42.5013.7017.700.002.3080.000.000.959-0.0600.008
call45.0011.3015.2010.102.0201.000.000.953-0.0580.009
call47.508.8012.700.001.7420.000.000.901-0.1030.016
call50.006.3010.305.251.5071.000.000.815-0.1750.024
call52.503.807.900.001.2660.000.000.778-0.1570.027
call55.001.504.902.550.8261,2450.000.714-0.1360.031
call57.501.201.901.190.3934097.000.603-0.0890.035
call60.000.350.700.400.3232,4013.000.352-0.0830.034
call62.500.050.200.080.3697133.000.187-0.0670.024
call65.000.000.750.100.5112393.000.095-0.0450.015
call67.500.001.150.030.63958.000.000.079-0.0490.013
call70.000.002.150.050.75650325.000.069-0.0520.012
call72.500.002.150.080.86610.000.000.062-0.0550.011
call75.000.000.250.101.01115.000.000.055-0.0560.010
call80.000.002.150.050.9261,0360.000.017-0.0200.004
call85.000.000.050.051.0785.000.000.015-0.0210.003
call90.000.002.150.001.2100.000.000.014-0.0220.003
call95.000.002.150.001.3370.000.000.013-0.0230.003
put42.500.002.150.001.2410.000.00-0.041-0.0560.008
put45.000.000.200.051.4349.000.00-0.128-0.1420.020
put47.500.000.500.711.10142.000.00-0.099-0.0980.016
put50.000.002.500.251.2441050.00-0.185-0.1690.024
put52.500.002.200.960.99549.000.00-0.222-0.1510.027
put55.000.102.350.720.7402512.00-0.286-0.1300.031
put57.500.051.251.100.46123710.00-0.397-0.0830.035
put60.001.103.103.480.6005760.00-0.648-0.0760.034
put62.502.356.406.001.07350.000.00-0.813-0.0600.024
put65.004.908.805.401.2550.000.00-0.905-0.0380.015
put67.507.4011.300.001.4750.000.00-0.921-0.0410.013
put70.0010.0013.807.501.6480.000.00-0.931-0.0440.012
put72.5012.5016.300.001.8070.000.00-0.938-0.0470.011
put75.0015.0018.800.001.9550.000.00-0.944-0.0490.010
put80.0020.0023.800.002.2240.000.00-0.983-0.0120.004
put85.0024.9028.800.002.4660.000.00-0.985-0.0120.003
put90.0029.9033.800.002.6450.000.00-0.986-0.0120.003
put95.0035.0038.800.002.8850.000.00-0.987-0.0120.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-04SCHEDULE 13G/ASEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-068-KCurrent report2026-10-06SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-308-KCurrent report2026-09-24SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-143Initial statement of beneficial ownership of securities2026-09-10SEC
2026-09-148-KCurrent report2026-09-10SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-018-KCurrent report2026-08-31SEC
2026-08-318-KCurrent report2026-08-30SEC
2026-08-188-KCurrent report2026-08-17SEC
2026-08-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-138-K/A2026-04-27SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-048-KCurrent report2026-06-02SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001.16M1
2026-080000
2026-070000
2026-060000
2026-0500176.68K1
2026-040000
2026-0300996.74K1
2026-02001.98M2
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.10.58%
DODGE & COX7.68%
PRIMECAP MANAGEMENT CO/CA/7.34%
VANGUARD CAPITAL MANAGEMENT LLC4.52%
VANGUARD PORTFOLIO MANAGEMENT LLC4.47%
NORGES BANK4.25%
STATE STREET CORP4.04%
VIKING GLOBAL INVESTORS LP3.94%
FMR LLC3.79%
Vestal Point Capital, LP3.12%

Funds

Fund% owned
Loomis Sayles Investment Grade Bond Fund28.95%
VANGUARD HIGH-YIELD CORPORATE FUND28.95%
American High Income Trust21.96%
American Funds Multi-Sector Income Fund13.92%
BlackRock High Yield Portfolio10.98%
NYLIM MacKay Convertible Fund10.13%
Fidelity Advisor Floating Rate High Income Fund8.93%
iShares Broad USD High Yield Corporate Bond ETF8.91%
Loomis Sayles Income Fund7.47%
American Funds Strategic Bond Fund7.33%

OakChart. BMRN. Cached 15 minutes.